Michael Schneider

Mike Schneider is an experienced health care executive with over 20 years of experience in pharmaceutical manufacturer, pharmacy benefit manager, and payer side of health care.


He was a director of Industry Relations at CVS Health with responsibility for trade strategy development, rebate negotiations, and contract execution for CVS Caremark’s own Medicare Part D Plans and that of its clients.  He held a similar position at Universal American before it was acquired by CVS Health, where he also negotiated UA’s commercial business.  Mike has also held various sales and market access with pharmaceutical manufacturers with increasing responsibility. Before entering health care, Mike began his career as a researcher at the Procter & Gamble Company in Cincinnati, Ohio, where he worked on hair care product formulation development focusing on the key markets of China and Japan, and then moved on to work in drug development.

Mikee holds a BS degree from the University of Illinois and an MBA from the University of Akron.

Authored Content

In the fourth episode of the Specialty Pharmacy Stakeholder Perspectives podcast series, Avalere is joined by Adam Hanauer, Associate Vice President at Humana Specialty Pharmacy, and Mark Sasala, Principal Business Analyst of Products at Creehan & Company, to discuss the outlook of specialty pharmacy with a focus on the environmental considerations and potential impacts of COVID-19.

In the first episode of the Specialty Pharmacy Stakeholder Perspectives series, Avalere is joined by Joel Wright, CEO at AllianceRx and Ernie Shopes, SVP Products and Client Delivery at Creehan and Company, discussing the outlook for specialty pharmacy, including a focus on trends in the pipeline and overall landscape.

Avalere experts examined evolving stakeholder-specific considerations for reshaping how patients with autoimmune conditions receive care during and after the COVID-19 pandemic.

The large-scale disruptions resulting from COVID-19 are significantly reshaping how patients receive care. In particular, patients taking infused and injectable drugs administered by a healthcare professional at a physician office, infusion center, or hospital outpatient department now face greater challenges receiving their medications.

Just because we can’t meet at sPCMA doesn’t mean we can’t discuss what’s next for Medicare Part D.

Implementation of a preferred specialty tier could have various impacts on Part D plans’ formulary and benefit designs and could affect manufacturer contracting strategies.

ICER is eager to position itself as the primary comparative and cost-effectiveness research body in the US. While their activity has been traditionally more limited to product-specific reviews, the Institute is increasingly looking to shape the broader debate around value and drug pricing.

Manufacturers currently face an almost-unprecedented level of uncertainty in developing contracting strategies for the coming plan years. Avalere’s combination of policy and commercialization expertise, paired with its data capabilities, allow us to support life sciences companies understand this challenging landscape to ensure access to innovative therapies for their patients.